Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more
Agios Pharmaceuticals, Inc. (0HB0) - Total Assets
Latest total assets as of September 2025: $1.39 Billion USD
Based on the latest financial reports, Agios Pharmaceuticals, Inc. (0HB0) holds total assets worth $1.39 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Agios Pharmaceuticals, Inc. - Total Assets Trend (2012–2024)
This chart illustrates how Agios Pharmaceuticals, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Agios Pharmaceuticals, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Agios Pharmaceuticals, Inc.'s total assets of $1.39 Billion consist of 58.1% current assets and 41.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.6% |
| Accounts Receivable | $4.11 Million | 0.3% |
| Inventory | $27.62 Million | 1.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Agios Pharmaceuticals, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Agios Pharmaceuticals, Inc.'s current assets represent 58.1% of total assets in 2024, a decrease from 95.0% in 2012.
- Cash Position: Cash and equivalents constituted 4.6% of total assets in 2024, down from 66.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 1.7% of total assets.
Agios Pharmaceuticals, Inc. Competitors by Total Assets
Key competitors of Agios Pharmaceuticals, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Agios Pharmaceuticals, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Agios Pharmaceuticals, Inc. generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Agios Pharmaceuticals, Inc. generates $ 40.51 in net profit.
Agios Pharmaceuticals, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.82 | 8.99 | 6.74 |
| Quick Ratio | 13.39 | 8.77 | 6.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $958.35 Million | $ 954.74 Million | $ 542.28 Million |
Agios Pharmaceuticals, Inc. - Advanced Valuation Insights
This section examines the relationship between Agios Pharmaceuticals, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | 77.5% |
| Total Assets | $1.66 Billion |
| Market Capitalization | $1.49 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Agios Pharmaceuticals, Inc.'s assets close to their book value ( 0.90x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Agios Pharmaceuticals, Inc.'s assets grew by 77.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Agios Pharmaceuticals, Inc. (2012–2024)
The table below shows the annual total assets of Agios Pharmaceuticals, Inc. from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.66 Billion | +77.48% |
| 2023-12-31 | $937.12 Million | -24.35% |
| 2022-12-31 | $1.24 Billion | -13.84% |
| 2021-12-31 | $1.44 Billion | +68.56% |
| 2020-12-31 | $852.95 Million | -4.24% |
| 2019-12-31 | $890.74 Million | +3.76% |
| 2018-12-31 | $858.46 Million | +39.72% |
| 2017-12-31 | $614.40 Million | -0.76% |
| 2016-12-31 | $619.09 Million | +47.38% |
| 2015-12-31 | $420.06 Million | -14.60% |
| 2014-12-31 | $491.90 Million | +144.48% |
| 2013-12-31 | $201.21 Million | +46.86% |
| 2012-12-31 | $137.01 Million | -- |